Tag: growth stock
-
![The Core Story: InPlay Oil (IPO.T) riding a sector rise with 6% dividend yield]()
The Core Story: InPlay Oil (IPO.T) riding a sector rise with 6% dividend yield
We liked InPlay Oil a few years back when they said they’d use their debt to grow hard, acquire good oil and gas properties in Alberta, and generate enough revenue (even in lean times) to return funds to shareholders. Many sniffed at that goal, but IPO.T has made it happen, building a cash flow machine…
-
![Medexus (MDP.V) by Mackie Research upgrades their target price by 42%]()
Medexus (MDP.V) by Mackie Research upgrades their target price by 42%
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech is not an easy industry to understand. The jargon used by those writing about the industry often takes away from the ingenious business models of some…
-
![Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases]()
Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases
In 25% of Breast Lumpectomy surgeries, cancerous material is left behind. With current technology, the surgeon needs to wait about a week, to see if he’s got all the cancerous material.
-
Medexus Pharmaceuticals (MDP.V), Flexing its deal making muscles
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed an important deal that has relevancy for blood cancer treatments, but it’s also upsized its current financing – a financial move that’s indicative of the growing…
-
![PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)]()
PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of course, this doesn’t change the fact that we’re still big on holding people accountable – client or not. See recent example here.) PMED as a business…
-
Medexus Pharmaceuticals (MDP.V), poised for flight on the Nasdaq (coming soon)
If you are like me and health sciences is your sector of choice when it comes to investing in the markets, you’d better be very patient, love doing research – and a willingness to see it through!!! A sector famous for its high-risk-high-reward characteristics is definitely not recommended for the faint of heart. Lucky for…
-
Perimeter Medical Imaging AI (PINK.V): the power of a simple story
No need to cut the patient open again later. The surgeon can make adjustments on the fly.
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
-
Perimeter Medical Imaging AI (PINK.V) shuffles the deck
PINK is accelerating toward the commercialisation of the OTIS platform. It has already received a $7.4 million grant (non-dilutive capital) from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the ATLAS AI Project.
-
Perimeter Medical Imaging AI (PINK.V) untapped value in medtech
Investing your money in health or medical companies is difficult. The complexity of the science often deters investors from allocating a portion of their portfolio to said industry, despite those companies having proven potential to provide the largest gains for its investors. We’re not criticizing – everyone knows that medical terminology is only second to…
